Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidates SAN FRANCISCO, March 14, 2019-- Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine with a focus on specific control of the Wnt signaling pathway, today announced the successful completion of a $50 million Series B financing. The financing included, but was not limited to, new investors Horizons Ventures, Hartford HealthCare Endowment, and NS Investment. The Column Group, and other existing investors, participated as well.